Hongyu Tao

ORCID: 0000-0001-5127-2194
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Extracellular vesicles in disease
  • MicroRNA in disease regulation
  • RNA Interference and Gene Delivery
  • RNA modifications and cancer
  • Telomeres, Telomerase, and Senescence
  • Monoclonal and Polyclonal Antibodies Research
  • Tuberculosis Research and Epidemiology
  • Cancer-related molecular mechanisms research
  • Advanced biosensing and bioanalysis techniques
  • Cancer therapeutics and mechanisms
  • Cancer Immunotherapy and Biomarkers
  • Lung Cancer Treatments and Mutations
  • Protein purification and stability
  • RNA Research and Splicing
  • Ultrasound and Hyperthermia Applications
  • Inhalation and Respiratory Drug Delivery
  • Biochemical and Molecular Research
  • Cancer Research and Treatments
  • Nanoparticle-Based Drug Delivery
  • Synthesis and bioactivity of alkaloids
  • DNA Repair Mechanisms
  • Berberine and alkaloids research
  • Pancreatic and Hepatic Oncology Research
  • Cancer-related Molecular Pathways
  • Nanoplatforms for cancer theranostics

Guangzhou Medical University
2025

Chinese Academy of Medical Sciences & Peking Union Medical College
2021-2024

Ningxia Medical University General Hospital
2021

Ningxia Medical University
2021

Capital Medical University
2020

Guangxi Medical University
2020

Huazhong University of Science and Technology
2015

MiR-34a, which acts as an important tumor suppressor gene, plays role in pancreatic cancer. However, the therapeutic application of miR-34a is limited by lack effective delivery system. In present study, we synthesize exosomes-coated (exomiR-34a), and anticancer effect exomiR-34a was evaluated cancer.An ultrasound approach used to exomiR-34a, its transfection efficiency examined confocal microscopy flow cytometry. The level targeted gene Bcl-2 detected real-time quantitative PCR (qRT-PCR)....

10.2147/dddt.s265423 article EN cc-by-nc Drug Design Development and Therapy 2020-08-01

H2A.Z is an oncogenic histone variant that overexpressed in cancers. Two isoforms of H2A.Z, H2AFZ and H2AFV, are identical except for a three-amino acid difference. However, their isoform-specific functions remain unclear cancer development. Thereby, this study aimed to investigate whether the two play distinct hepatocarcinogenesis.Expressions 116 paired hepatocellular cancerous para-cancerous tissues were detected by employing qPCR. GEO TCGA databases used probe expressions prognostic value...

10.2147/ott.s243823 article EN OncoTargets and Therapy 2020-05-01

Abstract The metastasis of breast cancer is believed to have a negative effect on its prognosis. Benefiting from the remarkable deep-penetrating and noninvasive characteristics, sonodynamic therapy (SDT) demonstrates whole series potential leading treatment. To relieve limitation monotherapy, multifunctional nanoplatform has been explored realize synergistic treatment efficiency. Herein, we establish novel nano-system which encapsulates chlorin e6 (Ce6, for SDT), perfluoropentane (PFP,...

10.1186/s11671-021-03532-z article EN cc-by Nanoscale Research Letters 2021-04-29

Microvesicles (MVs) are submicrometric membrane fragments that can "engulf" cytoplasmic contents such as microRNAs (miRNAs) from their cellular origin. The study of miRNAs carried within MVs might provide insights into the roles play in underlying pathophysiologic processes acute lymphoblastic leu-kemia (ALL). We identified numerous dysregulated MV patients with B- and T-cell ALL by using Agilent microarray analysis. Selected obtained profiling were validated us-ing quantitative reverse...

10.4238/2015.october.5.2 article EN Genetics and Molecular Research 2015-01-01

The present study aimed to evaluate the anti-tumor efficacy of epidermal growth factor receptor (EGFR)-targeting recombinant fusion protein Fv-LDP-D3 and its antibody-drug conjugate Fv-LDP-D3-AE against esophageal cancer. Fv-LDP-D3, consisting fragment variable (Fv) an anti-EGFR antibody, apoprotein lidamycin (LDP), third domain human serum albumin (D3), exhibited a high binding affinity for EGFR-overexpressing cancer cells, inhibited EGFR phosphorylation down-regulated inosine monophosphate...

10.1080/10717544.2022.2063454 article EN cc-by Drug Delivery 2022-04-13
Coming Soon ...